Gui Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gui Yang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ping-Chang Yang
Institute of Allergy & Immunology Shenzhen University Shenzhen China
4 shared publications Bai-Ling Xie
Guangdong Provincial Key Laboratory of Regional Immunity and Diseases
1 shared publicationBeiping Miao
Department of Otolaryngology, Head & Neck Surgery, Shenzhen Second People’s Hospital
1 shared publicationCai-Jie Zhou
Shenzhen Hospital
1 shared publication- Da-Bo Liu
Department of Pediatric Otolaryngology, Shenzhen Hospital, Southern Medical University, Shenzhen, China
1 shared publication Gaohui Wu
Shenzhen Univ, Affiliated Hosp 3, Dept Gen Practice Med & Allergy, Shenzhen, Peoples R China
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1858675
Free Epstein-Barr virus-induced gene 3 functions as an autonomous immunosuppressive cytokine to maintain immune tolerance
Epstein-Barr virus-induced gene 3(EBI3) is conventionally viewed as a subunit of IL-27 and IL-35, yet the function of uncomplexed “free” EBI3 is unknown. We show that free EBI3 is an autonomous immunosuppressive cytokine that acts via a gp130/WSX-1/STAT3 axis and epigenetic reprogramming. A free-EBI3-specific sandwich ELISA revealed 23.3 ± 2.2 ng/mL in healthy human sera and equivalent levels in mice; no cross-reactivity with IL-27/IL-35 was observed. Serum free EBI3 was reduced in rheumatoid arthritis(RA; 12.4 ± 1.4 ng/mL) and multiple sclerosis (MS; 14.6 ± 1.4 ng/mL; both p< 0.001) and inversely correlated with disease activity(RA-DAS28-ESR r=-0.67; MS-EDSS r=-0.61). Baseline-/- mice developed spontaneous colitis and severe EAE; daily free EBI3(1 mg/kg) reversed pathology, whereas IL-27/IL-35 did not. Tissue-targeted delivery(liposomes or nanoparticles) outperformed systemic therapy. Ex-vivo free EBI3 normalized RA/MS patient PBMCs(proliferation-50%; IL-17-52%; p< 0.001). Thus, free EBI3 is a distinct cytokine whose gp130/WSX-1 axis constitutes a biomarker and therapeutic target for inflammatory diseases.
- 27 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1858675
Open AccessFree Epstein-Barr virus-induced gene 3 functions as an autonomous immunosuppressive cytokine to maintain immune tolerance
Epstein-Barr virus-induced gene 3(EBI3) is conventionally viewed as a subunit of IL-27 and IL-35, yet the function of uncomplexed “free” EBI3 is unknown. We show that free EBI3 is an autonomous immunosuppressive cytokine that acts via a gp130/WSX-1/STAT3 axis and epigenetic reprogramming. A free-EBI3-specific sandwich ELISA revealed 23.3 ± 2.2 ng/mL in healthy human sera and equivalent levels in mice; no cross-reactivity with IL-27/IL-35 was observed. Serum free EBI3 was reduced in rheumatoid arthritis(RA; 12.4 ± 1.4 ng/mL) and multiple sclerosis (MS; 14.6 ± 1.4 ng/mL; both p< 0.001) and inversely correlated with disease activity(RA-DAS28-ESR r=-0.67; MS-EDSS r=-0.61). Baseline-/- mice developed spontaneous colitis and severe EAE; daily free EBI3(1 mg/kg) reversed pathology, whereas IL-27/IL-35 did not. Tissue-targeted delivery(liposomes or nanoparticles) outperformed systemic therapy. Ex-vivo free EBI3 normalized RA/MS patient PBMCs(proliferation-50%; IL-17-52%; p< 0.001). Thus, free EBI3 is a distinct cytokine whose gp130/WSX-1 axis constitutes a biomarker and therapeutic target for inflammatory diseases.
- 12 July 2023
- Published by Elsevier in Molecular Immunology
- Vol. 160, 161-167
5-HT modulates the properties of dendritic cells to interfere with the development of type 1 regulating T cells
- 12 July 2023
- Published by Elsevier in Molecular Immunology
- Vol. 160, 161-167
5-HT modulates the properties of dendritic cells to interfere with the development of type 1 regulating T cells
- 27 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 16 (791) , eabm9454
The transcription factor XBP1 in dendritic cells promotes the T H 2 cell response in airway allergy
Dendritic cells (DCs) that express T cell immunoglobulin domain molecule-4 (TIM4), a cell surface receptor for phosphatidylserine, induce T helper 2 (T H 2) cell responses and allergic reactions. We elucidated the role of the transcription factor X-box–binding protein-1 (XBP1) in the induction of the T H 2 cell response through its role in generating TIM4 + DCs. We found that XBP1 was required for TIM4 mRNA and protein expression in airway DCs in response to the cytokine interleukin-2 (IL-2) and that this pathway was required for TIM4 expression on DCs in response to the allergens PM2.5 and Derf1. The IL-2–XBP1–TIM4 axis in DCs contributed to Derf1/PM2.5-induced, aberrant T H 2 cell responses in vivo. An interaction between the guanine nucleotide exchange factor Son of sevenless-1 (SOS1) and the GTPase RAS promoted XBP1 and TIM4 production in DCs. Targeting the XBP1-TIM4 pathway in DCs prevented or alleviated experimental airway allergy. Together, these data suggest that XBP1 is required for T H 2 cell responses by inducing the development of TIM4 + DCs, which depends on the IL-2–XBP1–SOS1 axis. This signaling pathway provides potential therapeutic targets for the treatment of T H 2 cell–dependent inflammation or allergic diseases.
- 27 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 16 (791) , eabm9454
The transcription factor XBP1 in dendritic cells promotes the T H 2 cell response in airway allergy
Dendritic cells (DCs) that express T cell immunoglobulin domain molecule-4 (TIM4), a cell surface receptor for phosphatidylserine, induce T helper 2 (T H 2) cell responses and allergic reactions. We elucidated the role of the transcription factor X-box–binding protein-1 (XBP1) in the induction of the T H 2 cell response through its role in generating TIM4 + DCs. We found that XBP1 was required for TIM4 mRNA and protein expression in airway DCs in response to the cytokine interleukin-2 (IL-2) and that this pathway was required for TIM4 expression on DCs in response to the allergens PM2.5 and Derf1. The IL-2–XBP1–TIM4 axis in DCs contributed to Derf1/PM2.5-induced, aberrant T H 2 cell responses in vivo. An interaction between the guanine nucleotide exchange factor Son of sevenless-1 (SOS1) and the GTPase RAS promoted XBP1 and TIM4 production in DCs. Targeting the XBP1-TIM4 pathway in DCs prevented or alleviated experimental airway allergy. Together, these data suggest that XBP1 is required for T H 2 cell responses by inducing the development of TIM4 + DCs, which depends on the IL-2–XBP1–SOS1 axis. This signaling pathway provides potential therapeutic targets for the treatment of T H 2 cell–dependent inflammation or allergic diseases.
- Open Access
- 10 December 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Short-Chain Fatty Acids Promote Immunotherapy by Modulating Immune Regulatory Property in B Cells
The dysfunction of regulatory B cells (Breg) may result in immune inflammation such as allergic rhinitis (AR); the underlying mechanism is not fully understood yet. Short-chain fatty acids, such as propionic acid (PA), have immune regulatory functions. This study is aimed at testing a hypothesis that modulates PA production alleviating airway allergy through maintaining Breg functions. B cells were isolated from the blood obtained from AR patients and healthy control (HC) subjects. The stabilization of IL-10 mRNA in B cells was tested with RT-qPCR. An AR mouse model was developed to test the role of PA in stabilizing the IL-10 expression in B cells. We found that the serum PA levels were negatively correlated with the serum Th2 cytokine levels in AR patients. Serum PA levels were positively associated with peripheral CD5+ B cell frequency in AR patients; the CD5+ B cells were also IL-10+. The spontaneous IL-10 mRNA decay was observed in B cells, which was prevented by the presence of PA through activating GPR43. PA counteracted the effects of Tristetraprolin (TTP) on inducing IL-10 mRNA decay in B cells through the AKT/T-bet/granzyme B pathway. Administration of Yupinfeng San, a Chinese traditional medical formula, or indole-3-PA, induced PA production by intestinal bacteria to stabilize the IL-10 expression in B cells, which promoted the allergen specific immunotherapy, and efficiently alleviated experimental AR. In summary, the data show that CD5+ B cells produce IL-10. The serum lower PA levels are associated with the lower frequency of CD5+ B cells in AR patients. Administration with Yupinfeng San or indole-3-PA can improve Breg functions and alleviate experimental AR.
- 10 December 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-13
Open AccessShort-Chain Fatty Acids Promote Immunotherapy by Modulating Immune Regulatory Property in B Cells
The dysfunction of regulatory B cells (Breg) may result in immune inflammation such as allergic rhinitis (AR); the underlying mechanism is not fully understood yet. Short-chain fatty acids, such as propionic acid (PA), have immune regulatory functions. This study is aimed at testing a hypothesis that modulates PA production alleviating airway allergy through maintaining Breg functions. B cells were isolated from the blood obtained from AR patients and healthy control (HC) subjects. The stabilization of IL-10 mRNA in B cells was tested with RT-qPCR. An AR mouse model was developed to test the role of PA in stabilizing the IL-10 expression in B cells. We found that the serum PA levels were negatively correlated with the serum Th2 cytokine levels in AR patients. Serum PA levels were positively associated with peripheral CD5+ B cell frequency in AR patients; the CD5+ B cells were also IL-10+. The spontaneous IL-10 mRNA decay was observed in B cells, which was prevented by the presence of PA through activating GPR43. PA counteracted the effects of Tristetraprolin (TTP) on inducing IL-10 mRNA decay in B cells through the AKT/T-bet/granzyme B pathway. Administration of Yupinfeng San, a Chinese traditional medical formula, or indole-3-PA, induced PA production by intestinal bacteria to stabilize the IL-10 expression in B cells, which promoted the allergen specific immunotherapy, and efficiently alleviated experimental AR. In summary, the data show that CD5+ B cells produce IL-10. The serum lower PA levels are associated with the lower frequency of CD5+ B cells in AR patients. Administration with Yupinfeng San or indole-3-PA can improve Breg functions and alleviate experimental AR.